Recruiting
Phase 2

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Sponsor:

University of South Florida

Code:

NCT04430179

Conditions

Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information